Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.

Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedite their research and development as remedies for severe mental

Novartis has axed two late-stage programs in cancer-related blood clots after observing “inferior efficacy” in a clinical trial. The move marks a setback for a

Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of

The investor Venrock will make $900 million on a relatively small $20 million investment into Kelonia Therapeutics, which on Monday agreed to sell itself to